MedTrace Logo

Effect of Vilanterol on Methacholine Challenge Results

NCT03315000 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2018-10-11

No results posted yet for this study

Summary

The study will assess the degree of bronchoprotection provided by the ultra long-acting beta2 agonist vilanterol against methacholine-induced bronchoconstriction.

Conditions

Interventions

DRUG

Vilanterol and Fluticasone Furoate

Same as vilanterol arm description

DRUG

Fluticasone Furoate

Same as fluticasone arm description

DRUG

Placebos

Same as placebo arm description

Sponsors & Collaborators

  • University of Saskatchewan

    lead OTHER

Principal Investigators

  • Don Cockcroft, MD · University of Saskatchewan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-13
Primary Completion
2018-05-01
Completion
2018-05-01

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03315000 on ClinicalTrials.gov